Previous 10 | Next 10 |
Prothena (PRTA) announces positive results from Phase 1 study of PRX004 in patients with hereditary ATTR Amyloidosis (hATTR). Slowing of neuropathy progression was demonstrated by a mean change of +1.29 points in NIS at 9 months, compared to +9.2 points in untreated and placebo-treated patien...
Slowing of neuropathy progression for all 7 evaluable patients, evidenced by a +1.29 point mean change in NIS, was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluable patients demonstrated by a mean change in NIS of -3.33 ...
Biotech stocks remain under pressure due to fear of persistently rising interest rates. Neurology is a complex area of biotech with great promise and significant challenges. New approaches are broadening out the innovative paths as the dominant beta amyloid thesis has lost ground....
DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that r...
DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced that i...
Prothena (PRTA) appointed Hideki Garren, MD, PhD, as Chief Medical Officer leading the clinical and medical organizations to advance its clinical pipeline."His experience leading several late-stage development programs in neurology and rare disease indications through registration a...
DUBLIN, Ireland, April 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced the ap...
Prothena (PRTA) shares closed up 16.8% to $25.40 after pricing an offering of 7.5M shares at $20.75/share.That was a discount of ~4.5% to Tuesday's close.Prothena's most advanced asset is birtamimab in phase 3 for AL (primary) amyloidosis. For further details see: Prothena clo...
Gainers: Aptose Biosciences (APTO) +65%, Brainstorm Cell Therapeutics (BCLI) +13%, Prothena (PRTA) +12%, Armata Pharmaceuticals (ARMP) +8%, Inventiva (IVA) +8%.Losers: Benitec Biopharma (BNTC) -24%, Second Sight Medical Products (EYES) -1...
Prothena (PRTA) prices offering of 3.5M shares at $20.75/share.The net proceeds from the offering will be ~$67.8M.Underwriters' option to purchase up to an additional 0.525M shares.The offering is expected to close by March 26.Shares -1% premarket.Previously (March 23): Prothen...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...